$AGIO
Agios Pharmaceuticals Inc

2013 Q2 Form 10-Q Financial Statement

#000119312513358412 Filed on September 05, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $6.268M $6.288M
YoY Change -0.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.840M $1.950M
YoY Change -5.64%
% of Gross Profit
Research & Development $12.96M $10.46M
YoY Change 23.85%
% of Gross Profit
Depreciation & Amortization $400.0K $200.0K
YoY Change 100.0%
% of Gross Profit
Operating Expenses $14.79M $12.41M
YoY Change 19.2%
Operating Profit -$8.526M -$6.123M
YoY Change 39.25%
Interest Expense $10.00K $20.00K
YoY Change -50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$8.521M -$6.101M
YoY Change 39.67%
Income Tax $99.00K -$588.0K
% Of Pretax Income
Net Earnings -$8.620M -$5.513M
YoY Change 56.36%
Net Earnings / Revenue -137.52% -87.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.317M -$1.579M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $99.30M
YoY Change
Cash & Equivalents $77.48M $96.12M
Short-Term Investments $21.80M
Other Short-Term Assets $3.200M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $102.5M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $3.818M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.624M
YoY Change
Total Long-Term Assets $8.719M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $102.5M
Total Long-Term Assets $8.719M
Total Assets $111.3M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.038M
YoY Change
Accrued Expenses $3.586M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.98M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $45.40M
YoY Change
Total Long-Term Liabilities $45.40M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $36.98M
Total Long-Term Liabilities $45.40M
Total Liabilities $82.40M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$89.89M
YoY Change
Common Stock $2.840M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$87.05M
YoY Change
Total Liabilities & Shareholders Equity $111.3M
YoY Change

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$8.620M -$5.513M
YoY Change 56.36%
Depreciation, Depletion And Amortization $400.0K $200.0K
YoY Change 100.0%
Cash From Operating Activities -$15.80M -$10.50M
YoY Change 50.48%
INVESTING ACTIVITIES
Capital Expenditures -$700.0K -$300.0K
YoY Change 133.33%
Acquisitions
YoY Change
Other Investing Activities $10.60M -$5.200M
YoY Change -303.85%
Cash From Investing Activities $9.900M -$5.500M
YoY Change -280.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 100.0K
YoY Change 0.0%
NET CHANGE
Cash From Operating Activities -15.80M -10.50M
Cash From Investing Activities 9.900M -5.500M
Cash From Financing Activities 100.0K 100.0K
Net Change In Cash -5.800M -15.90M
YoY Change -63.52%
FREE CASH FLOW
Cash From Operating Activities -$15.80M -$10.50M
Capital Expenditures -$700.0K -$300.0K
Free Cash Flow -$15.10M -$10.20M
YoY Change 48.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
770000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
54000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96122000
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3770266 shares
CY2012Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3770266 shares
CY2013Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
415000
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
78300000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3586000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3038000
CY2013Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1356000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
36979000
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2013Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1127000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
-87050000
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2836000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89885000
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25072000
CY2013Q2 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
38000
CY2013Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
288000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2013Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
104000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111252000
CY2013Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
5141000
CY2013Q2 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
10000
CY2013Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
45103000
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q2 us-gaap Assets Current
AssetsCurrent
102533000
CY2013Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
21798000
CY2013Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
571000
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1624000
CY2013Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
21794000
CY2013Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
2706000
CY2013Q2 us-gaap Assets
Assets
111252000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77481000
CY2013Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
21794000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2011000
CY2013Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2013Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1247000
CY2013Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
8000000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3818000
CY2013Q2 agio Number Of Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months
NumberOfAvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonths
22 Securities
CY2013Q2 agio Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
1000
CY2013Q2 agio Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
5000
CY2013Q2 agio Eligible Milestone Payments Receivable For Clinical Development
EligibleMilestonePaymentsReceivableForClinicalDevelopment
5000000
CY2013Q2 agio Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
688000
CY2013Q2 agio Number Of Individual Securities In Significant Unrealized Loss Position
NumberOfIndividualSecuritiesInSignificantUnrealizedLossPosition
0 Securities
CY2013Q2 agio Potential Milestone Payment Receivable Upon Early Clinical Development Milestone Event
PotentialMilestonePaymentReceivableUponEarlyClinicalDevelopmentMilestoneEvent
22500000
CY2013Q2 agio One Time Receivable Eligibility Upon Dosing Of Last Patient Under First Split Licensed Program
OneTimeReceivableEligibilityUponDosingOfLastPatientUnderFirstSplitLicensedProgram
25000000
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31074167 shares
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117661000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3616101 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3616101 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
78300000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1708000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
65000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3308000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
109000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35113000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1124000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-72024000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2012000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74037000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25072000
CY2012Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
65000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
343000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2012Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
85000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137008000
CY2012Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4875000
CY2012Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
15000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
57639000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
130144000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
36680000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
571000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
22000
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
36679000
CY2012Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
2706000
CY2012Q4 us-gaap Assets
Assets
137008000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91297000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
36679000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
922000
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1246000
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
13700000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3565000
CY2012Q4 agio Number Of Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months
NumberOfAvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonths
30 Securities
CY2012Q4 agio Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
1000
CY2012Q4 agio Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
2000
CY2012Q4 agio Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
410000
CY2012Q4 agio Number Of Individual Securities In Significant Unrealized Loss Position
NumberOfIndividualSecuritiesInSignificantUnrealizedLossPosition
0 Securities
dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001439222
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0100 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9185 pure
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.75
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.27
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
19731564 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M27D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3690669 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27803000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23452549 shares
us-gaap Revenues
Revenues
12536000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2690000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15850000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15559000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
23195000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19443000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
121200000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15572000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Net Income Loss
NetIncomeLoss
-15848000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
9000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
976000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1845000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
72000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3688000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12536000
us-gaap Share Based Compensation
ShareBasedCompensation
753000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3930000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3317000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12536000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13816000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
266000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-271000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13915000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24420000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
289000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
38086000
us-gaap Depreciation
Depreciation
723000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
753000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
289000
us-gaap Operating Expenses
OperatingExpenses
28108000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3595000
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
289000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
289000
agio Estimated Performance Period Of Agreement
EstimatedPerformancePeriodOfAgreement
P6Y
agio Available For Sale Investment Maturity Term Maximum
AvailableForSaleInvestmentMaturityTermMaximum
P1Y
agio Collaboration Revenue
CollaborationRevenue
12536000
agio Number Of Vendors Selling Similar Competitive Products
NumberOfVendorsSellingSimilarCompetitiveProducts
0 Vendor
agio Proportionate Revenue Recognized
ProportionateRevenueRecognized
124300000
agio Requirement To Appoint Number Of Development Candidate By Joint Research Committee
RequirementToAppointNumberOfDevelopmentCandidateByJointResearchCommittee
2 Candidate
agio Number Of Licensed Programs Type Under Collaboration Agreements
NumberOfLicensedProgramsTypeUnderCollaborationAgreements
3 Licensed_Program
agio Period Considered For Agreement Termination Notice
PeriodConsideredForAgreementTerminationNotice
P90D
agio Rent Expense Deferred During Period
RentExpenseDeferredDuringPeriod
36000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0113 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9905 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M13D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3302508 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26520000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.16
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23219492 shares
us-gaap Revenues
Revenues
12556000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-72000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10169000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11340000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
50649000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13739000
us-gaap Income Taxes Paid
IncomeTaxesPaid
3500000
us-gaap Investment Income Interest
InvestmentIncomeInterest
48000
us-gaap Revenue From Grants
RevenueFromGrants
20000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11388000
us-gaap Net Income Loss
NetIncomeLoss
-10144000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-167000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
308000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-25000
us-gaap Share Based Compensation
ShareBasedCompensation
189000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21539000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-8006000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-869000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
3317000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4927000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20014000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
3317000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-4513000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
55884000
us-gaap Depreciation
Depreciation
537000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
189000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-4513000
us-gaap Operating Expenses
OperatingExpenses
23944000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3595000
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
202000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1196000
agio Collaboration Revenue
CollaborationRevenue
12536000
agio Rent Expense Deferred During Period
RentExpenseDeferredDuringPeriod
17000
agio Reduction In Income Tax Liability Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxLiabilityDueToCarrybackOfDeferredTaxAssets
1200000
agio Reduction In Income Tax Benefit Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxBenefitDueToCarrybackOfDeferredTaxAssets
600000
CY2010Q2 agio Expiration Extension Period Under Collaboration Agreement
ExpirationExtensionPeriodUnderCollaborationAgreement
P2Y
CY2010Q2 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2014-04
CY2011Q4 agio Initial Agreement Period
InitialAgreementPeriod
P3Y
CY2011Q4 agio Date Of Extension Of Discovery Phase
DateOfExtensionOfDiscoveryPhase
2016-04
CY2011Q4 agio Extended Agreement Period
ExtendedAgreementPeriod
P4Y
CY2011Q4 agio Receipt Due To Agreement Amendment
ReceiptDueToAgreementAmendment
20000000
CY2011 agio Reversal Of Valuation Allowance On Deferred Tax Assets
ReversalOfValuationAllowanceOnDeferredTaxAssets
10700000
CY2012 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2012 agio Available For Sale Investment Maturity Term Maximum
AvailableForSaleInvestmentMaturityTermMaximum
P1Y
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0118 pure
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0480 pure
CY2012Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M1D
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3358172 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.18
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23219492 shares
CY2012Q2 us-gaap Revenues
Revenues
6288000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5520000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6101000
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7311000
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
22000
CY2012Q2 us-gaap Revenue From Grants
RevenueFromGrants
20000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6123000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-5513000
CY2012Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1948000
CY2012Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1785000
CY2012Q2 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2012Q2 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
1785000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10463000
CY2012Q2 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2012Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-2373000
CY2012Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000
CY2012Q2 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-2373000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
12411000
CY2012Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1798000
CY2012Q2 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
164000
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-588000
CY2012Q2 agio Collaboration Revenue
CollaborationRevenue
6268000
CY2012Q2 agio Reduction In Income Tax Liability Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxLiabilityDueToCarrybackOfDeferredTaxAssets
1200000
CY2012Q2 agio Reduction In Income Tax Benefit Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxBenefitDueToCarrybackOfDeferredTaxAssets
600000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0100 pure
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9185 pure
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M27D
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3722963 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.80
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23452549 shares
CY2013Q2 us-gaap Revenues
Revenues
6268000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8623000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8521000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10418000
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8526000
CY2013Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-8620000
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1836000
CY2013Q2 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12958000
CY2013Q2 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2013Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
99000
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
329000
CY2013Q2 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
99000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
14794000
CY2013Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1798000
CY2013Q2 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
99000
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
99000
CY2013Q2 agio Collaboration Revenue
CollaborationRevenue
6268000

Files In Submission

Name View Source Status
0001193125-13-358412-index-headers.html Edgar Link pending
0001193125-13-358412-index.html Edgar Link pending
0001193125-13-358412.txt Edgar Link pending
0001193125-13-358412-xbrl.zip Edgar Link pending
agio-20130630.xml Edgar Link completed
agio-20130630.xsd Edgar Link pending
agio-20130630_cal.xml Edgar Link unprocessable
agio-20130630_def.xml Edgar Link unprocessable
agio-20130630_lab.xml Edgar Link unprocessable
agio-20130630_pre.xml Edgar Link unprocessable
d582671d10q.htm Edgar Link pending
d582671dex311.htm Edgar Link pending
d582671dex312.htm Edgar Link pending
d582671dex321.htm Edgar Link pending
d582671dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending